Arca
Skip to content
Tools
Tools

PGA5: Pepsin A

Shows particularly broad specificity; although bonds involving phenylalanine and leucine are preferred, many others are also cleaved to some extent.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on PGA5, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Other 1

Approved1

  • Sucralfate

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        SucralfateApprovedAbbVieOtherInhibitorPepsin A inhibitor8

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Study of Chlorophyllin or Placebo With Standard Treatment for Late Radiation Induced Luminal Gastrointestinal Tract BleedingSucralfatePhase 3Not yet recruitingTata Memorial CentreSep 23, 2026
        Topical Application of Sucralfate in Promoting Healing of Esophageal Ulcers After Esophageal Varices LigationSucralfateNot applicableNot yet recruitingNational Cheng-Kung University HospitalJul 1, 2026
        Endoscopic Application of Hemostatic Drug Powder in Lower Gastrointestinal Bleeding: A Pilot StudySucralfateNot applicableNot yet recruitingNational Cheng-Kung University HospitalJul 1, 2026
        Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux DiseaseSucralfatePhase 4Not yet recruitingUniversity of MonsMay 28, 2026
        Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Tumor Bleeding: A Randomized Controlled TrialSucralfateNot applicableRecruitingNational Cheng-Kung University HospitalApr 20, 2026
        Esomeprazole Plus Sucralfate for Post-ESD Ulcer HealingSucralfatePhase 4Not yet recruitingLanZhou UniversityDec 31, 2025
        Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled TrialSucralfatePhase 4Not yet recruitingNational Cheng-Kung University HospitalDec 2, 2025
        Prevention of Post-sphincterotomy BleedingSucralfateNot applicableRecruitingNational Cheng-Kung University HospitalOct 30, 2023

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Gastroesophageal reflux disease0.37
        • Peptic ulcer disease0.37
        • Oral mucositis0.26
        • Arthropathy0.13
        • Oral ulcer0.07
        • Gastric carcinoma0.06
        • Anal fissure0.06
        • Cancer0.04
        • Non-small cell lung carcinoma0.03

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3295, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P0DJD9, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.